Mina Henes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1757364/publications.pdf

Version: 2024-02-01

1040056 1199594 12 214 9 12 citations h-index g-index papers 14 14 14 190 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Foul Ball Rates and Injuries at Major League Baseball Games: A Retrospective Analysis of Data from Three Stadiums. Prehospital and Disaster Medicine, 2022, 37, 277-283.	1.3	2
2	Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance. Journal of Molecular Biology, 2022, 434, 167503.	4.2	6
3	Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. Chemical Reviews, 2021, 121, 3238-3270.	47.7	40
4	Inhibiting HTLV-1 Protease: A Viable Antiviral Target. ACS Chemical Biology, 2021, 16, 529-538.	3 . 4	12
5	Discovery of Quinoxaline-Based P1–P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants. Journal of Medicinal Chemistry, 2021, 64, 11972-11989.	6.4	15
6	Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode. Biochemistry, 2021, 60, 2925-2931.	2.5	21
7	Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir. ACS Chemical Biology, 2020, 15, 342-352.	3.4	11
8	Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere. Journal of Medicinal Chemistry, 2020, 63, 8296-8313.	6.4	6
9	Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors. MBio, 2020, 11, .	4.1	15
10	HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2′ Ligands To Optimize Hydrogen Bonding in the Substrate Envelope. Journal of Medicinal Chemistry, 2019, 62, 8062-8079.	6.4	21
11	Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance. ACS Chemical Biology, 2019, 14, 2441-2452.	3.4	36
12	Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease. ACS Infectious Diseases, 2019, 5, 316-325.	3.8	27